RecruitingNot applicableNCT04047953

Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

Studying NON RARE IN EUROPE: Adenocarcinoma of stomach

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peking University Cancer Hospital & Institute
Principal Investigator
Jiafu ji, MD
Peking University Cancer Hospital & Institute
Intervention
Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1(drug)
Enrollment
95 enrolled
Eligibility
18-75 years · All sexes
Timeline
20192026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04047953 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Adenocarcinoma of stomach

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach

← Back to all trials